8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Dec 11, 2025·SEC
Material company update
Dec 4, 2025·SEC
KESTRA MEDICAL TECHNOLOGIES, LTD.(KMTS)Earnings, Financials & Key Ratios
KMTS•NASDAQ
$20.71
$1.21B mkt cap·Price updated May 6, 2026
AboutKestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.Show more
- Revenue$60M+115.1%
- EBITDA-$98M-33.9%
- Net Income-$114M-20.9%
- EPS (Diluted)-5.13-151.5%
- Gross Margin40.47%+3009.9%
- EBITDA Margin-164.52%+37.7%
- Operating Margin-177.84%+41.8%
- Net Margin-190.28%+43.8%
- ROE-55.41%
- ROIC-658.17%
- Debt/Equity0.22
- Interest Coverage-13.75-0.7%
KMTS Key Insights
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KMTS Price & Volume
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) stock price & volume — 10-year historical chart
Loading chart...
KMTS Growth Metrics
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM110.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-87.37%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-132.94%
Return on Capital
10 Years-567.83%
5 Years-567.83%
3 Years-614.47%
Last Year-78.58%
KMTS Recent Earnings
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/8 qtrs (33%)●Beat Revenue 1/8 qtrs (33%)
Q2 2026Latest
Mar 17, 2026EPS
$0.61
Est $0.60
-1.7%
Revenue
$25M
Est $23M
+7.3%
Q4 2025
Dec 11, 2025EPS
$0.62
Est $0.59
-4.4%
Revenue
$23M
Est $23M
-1.3%
Q4 2025
Sep 11, 2025EPS
$0.46
Est $0.66
+30.3%
Revenue
$19M
Est $21M
-6.5%
Q3 2025
Jul 17, 2025EPS
$1.05
Revenue
$17M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 17, 2026 | $0.61vs $0.60-1.7% | $25Mvs $23M+7.3% |
| Q4 2025 | Dec 11, 2025 | $0.62vs $0.59-4.4% | $23Mvs $23M-1.3% |
| Q4 2025 | Sep 11, 2025 | $0.46vs $0.66+30.3% | $19Mvs $21M-6.5% |
| Q3 2025 | Jul 17, 2025 | $1.05 | $17M |
Based on last 8 quarters of dataView full earnings history →
KMTS Peer Comparison
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) competitors in Patient monitoring and respiratory care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 EW | 47.97B | 83.20 | 45.46 | 11.55% | 17.64% | 10.35% | 0.07 | |
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AVNS | 1.15B | 24.72 | -16.93 | 1.95% | -9.69% | -8.91% | 0.17 | |
 IRTC | 3.87B | 117.70 | -84.68 | 26.24% | -3.53% | -20.6% | 4.79 |
Compare KMTS vs Peers
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KMTS Income Statement
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Apr'20 | Apr'21 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 7.63M | 27.81M | 59.81M | 83.72M |
| Revenue Growth % | - | - | - | 264.53% | 115.05% | 110.07% |
| Cost of Goods Sold | 0 | 0 | 18.28M | 27.45M | 35.6M | 42.91M |
| COGS % of Revenue | - | - | 239.59% | 98.7% | 59.53% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -10.65M▲ 0% | 362K▲ 103.4% | 24.21M▲ 6587.8% | 40.81M▲ 0% |
| Gross Margin % | - | - | -139.59% | 1.3% | 40.47% | 48.75% |
| Gross Profit Growth % | - | - | - | 103.4% | 6587.85% | - |
| Operating Expenses | 29.32M | 32.71M | 69.77M | 85.42M | 130.59M | 184.42M |
| OpEx % of Revenue | - | - | 914.42% | 307.13% | 218.32% | - |
| Selling, General & Admin | 6.52M | 13.9M | 54.01M | 69.94M | 114.94M | 165.19M |
| SG&A % of Revenue | - | - | 707.92% | 251.44% | 192.15% | - |
| Research & Development | 22.8M | 18.81M | 15.76M | 15.49M | 15.65M | 19.24M |
| R&D % of Revenue | - | - | 206.5% | 55.69% | 26.17% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -29.32M▲ 0% | -32.71M▼ 11.6% | -80.42M▼ 145.9% | -85.06M▼ 5.8% | -106.38M▼ 25.1% | -143.61M▲ 0% |
| Operating Margin % | - | - | -1054.01% | -305.83% | -177.84% | -171.53% |
| Operating Income Growth % | - | -11.56% | -145.88% | -5.77% | -25.06% | - |
| EBITDA | -28.84M | -32.29M | -75.57M | -73.5M | -98.41M | -141.77M |
| EBITDA Margin % | - | - | -990.38% | -264.27% | -164.52% | -169.34% |
| EBITDA Growth % | - | -11.95% | -134.04% | 2.73% | -33.89% | -117.98% |
| D&A (Non-Cash Add-back) | 478K | 420K | 4.86M | 11.56M | 7.97M | 1.84M |
| EBIT | -29.32M | -32.75M | -78.59M | -87.87M | -105.94M | -103.98M |
| Net Interest Income | 0 | -1.17M | -5.63M | -6.23M | -4.54M | 46K |
| Interest Income | 0 | 0 | 0 | 0 | 3.2M | -4.47M |
| Interest Expense | 0 | 1.17M | 5.63M | 6.23M | 7.73M | 7.46M |
| Other Income/Expense | 0 | -1.21M | -3.8M | -9.03M | -7.3M | -75K |
| Pretax Income | -29.32M▲ 0% | -33.91M▼ 15.7% | -84.22M▼ 148.3% | -94.1M▼ 11.7% | -113.68M▼ 20.8% | -143.68M▲ 0% |
| Pretax Margin % | - | - | -1103.84% | -338.3% | -190.05% | -171.62% |
| Income Tax | 148K | 187K | 15K | 24K | 135K | 204K |
| Effective Tax Rate % | -0.5% | -0.55% | -0.02% | -0.03% | -0.12% | -0.14% |
| Net Income | -29.47M▲ 0% | -34.1M▼ 15.7% | -84.24M▼ 147.0% | -94.12M▼ 11.7% | -113.81M▼ 20.9% | -144.83M▲ 0% |
| Net Margin % | - | - | -1104.04% | -338.39% | -190.28% | -172.99% |
| Net Income Growth % | - | -15.73% | -147.03% | -11.73% | -20.92% | -87.37% |
| Net Income (Continuing) | -29.47M | -34.1M | -84.24M | -94.12M | -113.81M | -109.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.59▲ 0% | -0.69▼ 16.9% | -1.75▼ 153.6% | -2.04▼ 16.6% | -5.13▼ 151.5% | -2.74▲ 0% |
| EPS Growth % | - | -16.95% | -153.62% | -16.57% | -151.47% | -132.94% |
| EPS (Basic) | -0.59 | -0.69 | -1.75 | -2.04 | -5.13 | - |
| Diluted Shares Outstanding | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M | 52.84M |
| Basic Shares Outstanding | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M | 52.84M |
| Dividend Payout Ratio | - | - | - | - | - | - |
KMTS Balance Sheet
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Apr'20 | Apr'21 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 6.17M | 26.2M | 18.42M | 14.91M | 255.33M | 314.06M |
| Cash & Short-Term Investments | 5.76M | 24.34M | 14.81M | 8.25M | 237.59M | 291.32M |
| Cash Only | 5.76M | 24.34M | 14.81M | 8.25M | 237.59M | 291.32M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 2.11M | 2M | 8.08M | 12.71M |
| Days Sales Outstanding | - | - | 101.08 | 26.22 | 49.31 | 44.09 |
| Inventory | 0 | 0 | 2.11M | 3.29M | 6.57M | 0 |
| Days Inventory Outstanding | - | - | 42.19 | 43.74 | 67.37 | 13.98 |
| Other Current Assets | 209K | 1.34M | -1.74M | 419K | 1.69M | 10.03M |
| Total Non-Current Assets | 1.71M | 4.33M | 20.23M | 31.04M | 40.42M | 65.28M |
| Property, Plant & Equipment | 1.13M | 3.08M | 16.72M | 28.39M | 36.91M | 57.22M |
| Fixed Asset Turnover | - | - | 0.46x | 0.98x | 1.62x | 1.82x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 580K | 1.24M | 3.51M | 2.65M | 3.51M | 18.15M |
| Total Assets | 7.87M▲ 0% | 30.52M▲ 287.7% | 38.66M▲ 26.6% | 45.95M▲ 18.9% | 295.74M▲ 543.6% | 379.34M▲ 0% |
| Asset Turnover | - | - | 0.20x | 0.61x | 0.20x | 0.28x |
| Asset Growth % | - | 287.68% | 26.65% | 18.87% | 543.64% | 898.02% |
| Total Current Liabilities | 4.02M | 6.61M | 36.74M | 32.97M | 37.98M | 42.93M |
| Accounts Payable | 1.83M | 1.7M | 6.16M | 23.89M | 23.96M | 24.02M |
| Days Payables Outstanding | - | - | 123.03 | 317.67 | 245.63 | 184.52 |
| Short-Term Debt | 0 | 0 | 20.45M | 0 | 187K | 10K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 4.67M | 6.19M | 8.49M | 42.92M |
| Current Ratio | 1.54x | 3.96x | 0.50x | 0.45x | 6.72x | 6.72x |
| Quick Ratio | 1.54x | 3.96x | 0.44x | 0.35x | 6.55x | 6.55x |
| Cash Conversion Cycle | - | - | 20.24 | -247.7 | -128.95 | -126.46 |
| Total Non-Current Liabilities | 0 | 22.15M | 119.5M | 222.35M | 52.36M | 48.42M |
| Long-Term Debt | 0 | 20.24M | 17.32M | 42.54M | 41.1M | 4.28M |
| Capital Lease Obligations | 0 | 1.55M | 0 | 2.63M | 3.03M | 6.09M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 360K | 102.17M | 177.19M | 8.24M | 143.19M |
| Total Liabilities | 4.02M | 28.76M | 156.23M | 255.33M | 90.34M | 91.35M |
| Total Debt | 452K | 22.85M | 39.13M | 45.17M | 44.31M | 4.29M |
| Net Debt | -5.3M | -1.49M | 24.32M | 36.92M | -193.28M | -287.04M |
| Debt / Equity | 0.12x | 12.94x | - | - | 0.22x | 0.22x |
| Debt / EBITDA | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | 2.02x |
| Interest Coverage | - | -28.00x | -14.29x | -13.65x | -13.75x | -13.93x |
| Total Equity | 3.86M▲ 0% | 1.77M▼ 54.2% | -117.58M▼ 6757.9% | -209.38M▼ 78.1% | 205.41M▲ 198.1% | 287.99M▲ 0% |
| Equity Growth % | - | -54.21% | -6757.87% | -78.08% | 198.1% | 579.14% |
| Book Value per Share | 0.08 | 0.04 | -2.37 | -4.23 | 4.15 | 5.45 |
| Total Shareholders' Equity | 3.86M | 1.77M | -117.58M | -209.38M | 205.41M | 287.99M |
| Common Stock | 1K | 1K | 1K | 1K | 51.35M | 58.35M |
| Retained Earnings | -135.98M | -170.08M | -312.31M | -406.44M | -520.25M | -613.03M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
KMTS Cash Flow Statement
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) cash flow — operating, investing & free cash flow history
| Line item | Apr'20 | Apr'21 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -30.29M | -29.89M | -69.64M | -72.23M | -77.61M | -77.61M |
| Operating CF Margin % | - | - | -912.74% | -259.71% | -129.75% | - |
| Operating CF Growth % | - | 1.31% | -132.96% | -3.72% | -7.44% | -60.2% |
| Net Income | -29.47M | -34.1M | -84.24M | -94.12M | -113.81M | -144.83M |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M | 8.22M |
| Stock-Based Compensation | 0 | 1.86M | 1.21M | 1.49M | 24.27M | 45.65M |
| Deferred Taxes | 0 | 0 | -45K | 12K | 64K | 0 |
| Other Non-Cash Items | 706K | 1.94M | 7.28M | 4.44M | 10.11M | 6.79M |
| Working Capital Changes | -2.01M | -19K | 1.3M | 4.39M | -6.2M | -3.46M |
| Change in Receivables | 0 | 0 | 0 | -2M | -8.78M | -1.33M |
| Change in Inventory | 0 | 0 | -733K | -1.18M | -3.44M | -766K |
| Change in Payables | -790K | -132K | 2.14M | 7.34M | 2.84M | -843K |
| Cash from Investing | -232K | -334K | -15.46M | -12.23M | -23.31M | -38.33M |
| Capital Expenditures | -232K | -336K | -15.46M | -12.51M | -23.59M | -33.27M |
| CapEx % of Revenue | - | - | 202.63% | 44.99% | 39.44% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 2K | 0 | 285K | 283K | -5.06M |
| Cash from Financing | 30.24M | 48.81M | 96.11M | 77.72M | 330.26M | 361.98M |
| Debt Issued (Net) | 0 | 20M | -5.33M | 5.88M | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | -1000K |
| Dividends Paid | -183K | -187K | -671K | -799K | -1.65M | -31K |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 30.42M | 29M | 0 | -2.35M | 12.73M | 387.01M |
| Net Change in Cash | -286K▲ 0% | 18.59M▲ 6598.6% | 11M▼ 40.8% | -6.74M▼ 161.2% | 229.35M▲ 3503.3% | 236.97M▲ 0% |
| Free Cash Flow | -30.52M▲ 0% | -30.23M▲ 1.0% | -85.1M▼ 181.5% | -84.75M▲ 0.4% | -101.2M▼ 19.4% | -119.95M▲ 0% |
| FCF Margin % | - | - | -1115.37% | -304.7% | -169.19% | -143.28% |
| FCF Growth % | - | 0.96% | -181.51% | 0.42% | -19.41% | -54.96% |
| FCF per Share | -0.62 | -0.61 | -1.72 | -1.71 | -2.04 | -2.04 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.88x | 0.83x | 0.77x | 0.68x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 3.63M | 0 | -3.6M |
| Taxes Paid | 70K | 214K | 12K | 43K | 0 | -38K |
KMTS Key Ratios
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -1212.91% | - | - | -55.41% | -68.83% |
| Return on Invested Capital (ROIC) | -8985.71% | - | - | -658.17% | -658.17% |
| Gross Margin | - | -139.59% | 1.3% | 40.47% | 48.75% |
| Net Margin | - | -1104.04% | -338.39% | -190.28% | -172.99% |
| Debt / Equity | 12.94x | - | - | 0.22x | 0.22x |
| Interest Coverage | -28.00x | -14.29x | -13.65x | -13.75x | -13.93x |
| FCF Conversion | 0.88x | 0.83x | 0.77x | 0.68x | 0.83x |
| Revenue Growth | - | - | 264.53% | 115.05% | 110.07% |
KMTS SEC Filings & Documents
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
KMTS Frequently Asked Questions
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported $83.7M in revenue for fiscal year 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) grew revenue by 115.1% over the past year. This is strong growth.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported a net loss of $144.8M for fiscal year 2025.
Dividend & Returns
Yes, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) pays a dividend with a yield of 0.16%. This makes it attractive for income-focused investors.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a return on equity (ROE) of -55.4%. Negative ROE indicates the company is unprofitable.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) had negative free cash flow of $120.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates